Evidence map›Paper›PMID 37017812›Full record

ArticleBreast cancer research and treatment2023

HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.

Harriet T Rothschild, Elle Clelland, Anne Patterson, Julissa Molina-Vega, Mandeep Kaur, W Fraser Symmans, Christopher J Schwartz, A Jo Chien, Rita A Mukhtar

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Harriet T RothschildSchool of Medicine, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-5311-2872
Elle ClellandSchool of Medicine, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-1439-0532
Anne PattersonDepartment of Surgery, University of California, 1825 4th Street, 3rd Floor, Box 1710, San Francisco, CA, 94143, USA.ORCID http://orcid.org/0000-0002-1416-7376
Julissa Molina-VegaDepartment of Surgery, University of California, 1825 4th Street, 3rd Floor, Box 1710, San Francisco, CA, 94143, USA.
Mandeep KaurSchool of Medicine, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-5544-5918
W Fraser SymmansDepartment of Pathology, MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1526-184X
Christopher J SchwartzDepartment of Pathology, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-8086-8429
A Jo ChienDepartment of Medicine, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-2978-6249
Rita A MukhtarDepartment of Surgery, University of California, 1825 4th Street, 3rd Floor, Box 1710, San Francisco, CA, 94143, USA. rita.mukhtar@ucsf.edu.ORCID http://orcid.org/0000-0001-8079-7846
University of California, San Francisco · USThe University of Texas MD Anderson Cancer Center · US

Funding

NRSA Training CoreTL1TR001871 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KANAYA, ALKA M., SOMSOUK, MA · 2016 to 2025
$10.1M
Identifying responders to chemotherapy in invasive lobular carcinoma of the breast: development of a multivariable clinical prediction toolK08CA256047 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MUKHTAR, RITA · 2021 to 2025
$1.3M
NCATS NIH HHS TL1 TR 001871NCATS NIH HHS TL1 TR001871NCI NIH HHS K08 CA256047NCI NIH HHS K08CA256047
6 · The paper itself

Abstract

purposeHER2 overexpression has a central role in breast cancer carcinogenesis and is associated with poor prognosis if untreated. Lately, identification of HER2-low breast cancer has been proposed to select patients for novel HER2-directed chemotherapy and includes cancers with immunohistochemistry 1 + or 2 + with negative FISH, encompassing approximately 55-60% of all breast carcinomas. In early-stage breast cancer, the prognostic significance of HER2 low-disease is less well understood, with a particular paucity of data evaluating the prevalence and implications of HER2-low status in invasive lobular carcinoma (ILC).

methodsWe evaluated 666 stage I-III ILC tumors from a prospectively maintained institutional database, comparing clinicopathologic features and disease-free survival (DFS) using a multivariable Cox proportional hazards model.

resultsHER2-low status was common in this cohort of patients with ILC, but most clinicopathologic features did not differ between HER2-low and HER2-negative cases. However, when adjusting for tumor size, number of positive nodes, ER/PR status, and local therapy received, patients with HER2-low status had worse disease-free survival (DFS) than those with HER2-negative tumors (hazard ratio 2.0, 95% confidence interval 1.0-4.1, p = 0.05).

conclusionThis difference in DFS supports the notion that HER2-low and HER2-negative early stage ILC may differ clinically, despite similar clinicopathologic features. Further investigation into the potential benefit of HER2 targeted therapy in HER2-low early-stage breast cancer, and specifically lobular cancer, is warranted to ensure optimal outcomes in this distinct tumor subtype.

Indexed as

Breast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularDisease-Free SurvivalErb-b2 Receptor Tyrosine KinasesFemaleHumansPrognosisErb-b2 Receptor Tyrosine KinasesEarly-stageHER2-lowInvasive lobular carcinoma

Identifiers

PMID37017812
PMCPMC10175465
OpenAlexW4362601460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.